0RU5 Stock Overview
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.16 |
| 52 Week High | kr2.07 |
| 52 Week Low | kr0.077 |
| Beta | 1.4 |
| 1 Month Change | -7.26% |
| 3 Month Change | -43.02% |
| 1 Year Change | -92.29% |
| 3 Year Change | -99.45% |
| 5 Year Change | n/a |
| Change since IPO | -99.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RU5 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.3% |
| 1Y | -92.3% | -29.5% | 0.6% |
Return vs Industry: 0RU5 underperformed the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0RU5 underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0RU5 volatility | |
|---|---|
| 0RU5 Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RU5's share price has been volatile over the past 3 months.
Volatility Over Time: 0RU5's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 25 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.
BerGenBio ASA Fundamentals Summary
| 0RU5 fundamental statistics | |
|---|---|
| Market cap | kr613.67m |
| Earnings (TTM) | -kr190.40m |
| Revenue (TTM) | kr354.00k |
1,734x
P/S Ratio-3.2x
P/E RatioIs 0RU5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RU5 income statement (TTM) | |
|---|---|
| Revenue | kr354.00k |
| Cost of Revenue | kr0 |
| Gross Profit | kr354.00k |
| Other Expenses | kr190.76m |
| Earnings | -kr190.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 100.00% |
| Net Profit Margin | -53,785.59% |
| Debt/Equity Ratio | 0% |
How did 0RU5 perform over the long term?
See historical performance and comparison